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Synopsis 
Outpatient parenteral antimicrobial therapy (OPAT) is an established treatment option for patients 
with a variety of infections who require a period of intravenous therapy, are clinically stable, and do 
not require continuous monitoring. Many patients with fungal infections require prolonged therapy 
due to resistance or intolerance to oral antifungal agents. Despite the widespread use of OPAT by 
infection specialists, antifungal agents appear infrequently used in this setting. We suggest that with 
appropriate patient selection, patients with fungal infections could successfully be treated on OPAT. 
 
Introduction 
Outpatient parenteral antimicrobial therapy (OPAT), the administration of intravenous 
antimicrobials to patients in the ambulatory setting, has become established as a suitable alternative 
to inpatient therapy in appropriate patients [1, 2]. Generally, patients selected for OPAT require a 
period of several days to weeks of parenteral therapy for infections while remaining otherwise well, 
and fit for discharge from hospital [1]. Infections frequently treated via OPAT services include skin 
and soft tissue infections, deep-seated infections (including osteoarticular and endovascular 
infections) and infections caused by resistant organisms where oral therapy is not possible (e.g. in 
the treatment of infection caused by Extended Spectrum Beta-Lactamase producing organisms). The 
delivery of OPAT to patients varies widely; it may be delivered in the hospital setting, outpatient or 
ambulatory care clinics, or by administration at home by community nurses, carers or by patient 
self-administration. There is a growing body of evidence that OPAT is both safe and cost effective for 
a wide variety of infections [3], however while there is extensive experience of OPAT with 
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antibacterial agents, there is a paucity of evidence regarding the use of parenteral antifungal agents 
in OPAT programmes. 
 
Fungal infections requiring prolonged antimicrobial therapy (such as candidiasis, aspergillosis, 
cryptococcosis) are more likely to occur in patients with underlying co-morbidities, including 
immune compromise or other significant co-morbidities such as severe pulmonary disease, diabetes, 
or malignancy. Traditionally OPAT has not been selected for such patients, and this may account for 
the low rates of reported use of amphotericin B in the OPAT setting among infectious diseases 
physicians in the United States and Ireland; 47% and 14% respectively reported experience of using 
amphotericin B in OPAT [4, 5]. In many patients, therapy with triazole antifungals, which are 
available as oral agents, is the preferred treatment option; however, in certain circumstances the 
triazoles may not be appropriate due to resistance, toxicity, or drug-drug interactions. Additionally, 
the toxicity of antifungal agents may be a concern in an outpatient setting, and close monitoring or 
cautious adjustment of treatment on a frequent basis is required. This may be an additional barrier 
to OPAT in this patient cohort, particularly in less well-resourced OPAT programmes. The provision 
of parenteral antifungal therapy is possible in the OPAT setting provided there is careful and 
considered patient selection and appropriate safety monitoring and follow-up with an infection 
specialist is implemented.   
 
Patient Selection & monitoring 
The considerations for selecting suitable patients to receive antifungals via OPAT in the first instance 
are similar to those receiving antibacterial therapy. These factors have been covered extensively 
elsewhere [1, 2, 6], but in brief the site of infection, identified organism(s), co-morbidities, co-
prescribed medications, age, frailty and home circumstances (including home setting, family support 
and distance from hospital) must all be considered. The recommendation that patients who are 
considered for OPAT are assessed by clinicians experienced in OPAT is of vital importance in the 
administration of antifungal agents, given the likely complexity of infection and patient co-morbidity, 
and potential toxicity of intravenous antifungal agents [1, 2, 6]. We would contend that for 
antifungal therapy an infection specialist skilled in medical mycology be involved in the decision to 
discharge a patient on parenteral antifungal therapy (table 1). Additionally, clinicians should also be 
vigilant for potential drug-drug interactions; utilising on-line antifungal interaction checkers that are 
available, and pharmacy support to ameliorate such risks [7].  
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Factors associated with an increased risk of re-admission from OPAT include: infections with 
resistant organisms, aminoglycoside use, increasing age, and the number of hospital admissions in 
the last 12 months [8], however factors specific to antifungal agents are unknown.  Other evidence 
suggests that while OPAT in elderly patients is generally safe, re-admission due to de-stabilisation of 
medical co-morbidities is more common than in their younger counterparts, [9] highlighting that 
frailty should be a major consideration when assessing suitability for OPAT. These factors are 
equally, if not more important considerations when selecting patients to receive IV antifungal 
therapy in the OPAT setting.  
 
Regular clinical review is crucial aspect of patient management on OPAT [1, 2]. The purpose of 
regular clinical review is to evaluate clinical progress, early detection of adverse events such as those 
associated with intravascular catheters or side effects or toxicity of administered agent(s) and to 
determine treatment duration and cessation. Current recommendations are that clinical review is 
performed weekly by a member of the responsible team, however in certain circumstances longer 
follow-up duration may be reasonable depending on assessment and clinical judgement. To 
compliment clinical review, laboratory tests are required to monitor both response to treatment and 
for toxicity (table 2). Patients require weekly laboratory tests, although for patients receiving 
amphotericin B twice weekly renal function monitoring is recommended [2]. The review of such 
laboratory test results by an OPAT clinician has been associated with reduced rates of re-admission 
[10].  
 
Published studies of patients treated with antibacterial agents on OPAT suggest that readmission 
rates are between 6 and 31% of episodes, depending on the cohort of patients examined [11-14]. 
The reasons for readmission vary, with the most frequently reported reasons being complications of 
therapy, progression of infection, vascular access complications or reasons unrelated to OPAT/ 
infection being treated. Data relating to readmissions specific to antifungal agents is lacking, 
however in a small study of patients treated in the community with amphotericin B, 28 of 113 (25%) 
courses of treatment had to be discontinued and 13 of 113 (12%) courses resulted in hospital 
admission for nephroxicity, vascular access complications or electrolyte disturbances [15].  
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Antifungal Agents Suitable For OPAT 
With regards to antifungal agents that may be administered on OPAT, there are two main options: 
echinocandins (caspofungin, micafungin or anidulafungin) or liposomal amphotericin B. Oral triazole 
antifungals, possess good bioavailability, rendering parenteral administration necessary only in 
exceptional cases. However, significant variability in drug metabolism necessitates therapeutic drug 
monitoring with the triazoles, and such monitoring could be facilitated through the safety 
monitoring systems of an OPAT service; enhancing patient safety and optimising outcomes [16].  
 
Echinocandins have broad antifungal activity by inhibition of -1,3-D-glucan synthesis, with 
particularly potent fungicidal activity against Candida spp. but are fungistatic against Aspergillus spp. 
The three agents have similar once-daily dosing regimens and favourable toxicity profiles compared 
with amphotericin B [17]. The main adverse effects include infusion reactions, phlebitis, 
gastrointestinal upset and hepatotoxicity. 
 
Of the three echinocandins, caspofungin undergoes more extensive hepatic metabolism, requiring 
careful consideration of drug-drug interactions prior to commencing therapy [18]. Known 
interactions include reduction in serum tacrolimus levels when co-adminstered with caspofungin, 
while cyclosporin will increase serum levels of caspofungin. The use of enzyme inducing drugs such 
as rifampicin, phenytoin, efavirenz, and carbamazepine may reduce serum caspofungin levels. 
Considerations for the use of micafungin include the potential for hepatotoxicity and gastrointestinal 
disturbance, the incidence of hepatoxicity does not appear to differ between caspofungin and 
micafungin [19]. Less well recognised is the potential for electrolyte disturbances, in particular 
hyponatraemia that has been described in patients with chronic pulmonary aspergillosis early after 
the initiation of therapy [20].  Anidulafungin is not metabolised by the liver, so does not have the 
same propensity for hepatotoxicity and interactions, however hypomagnesaemia, hypokalaemia and 
headaches are common adverse events. Of the three agents, only micafungin does not require dose 
loading at the initiation of therapy [19]. A recent small study of patients with chronic pulmonary 
aspergillosis demonstrated that micafungin could be safely administered via OPAT [21].   
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The polyene antifungal amphotericin B has been in use for decades. While the agent possesses 
broad antifungal activity, including Candida spp., Aspergillus spp. (excluding Aspergillus terreus [22]), 
Zygomycetes, endemic fungi and Cryptococcus spp., clinical use is often limited by toxicity.  
 
The availability of lipid-based formulations of the drug have essentially replaced amphotericin B 
deoxycholate and resulted in marked improvement in the drug’s safety profile, albeit at increased 
cost. Adverse effects associated with amphotericin B include infusion-related reactions such as 
phlebitis, chills, vomiting, arrhythmias, hypotension and bronchospasm [23]. Electrolyte disturbance, 
nephrotoxicity, and anaemia are commonly reported adverse effects [24]. The risk of nephrotoxicity 
is increased with use of the deoxycholate preparation versus lipid-based formulations, total 
cumulative dose, administration of additional nephrotoxic agents and baseline renal dysfunction 
[25]. It has been postulated that administration of saline prior to infusion of amphotericin B may 
reduce the risk of nephrotoxicity [26].  
 
Prior to commencing therapy, a test dose is recommended to ensure the patient does not 
experience a severe hypersensitivity reaction [27]. Pre-treatment with hydrocortisone and 
chlorphenamine appears to reduce the incidence of infusion related effects [28]. Renal function 
should be monitored daily on initiation of therapy with amphotericin B [28], meaning that initiation 
of therapy may be challenging in the OPAT setting, and a period of hospital admission may be 
required to initiate therapy.  
 
Although there are specific indications for these agents, they are often used as second line therapy 
when patients cannot receive triazole therapy due to intolerance or resistance [18, 29]. Recent 
expert opinion on the management of triazole resistant Aspergillus fumigatus recommend therapy 
with either liposomal amphotericin B or an echinocandin combined with voriconazole [30]. With 
triazole resistance in Aspergillus fumigatus increasing worldwide [31], it is likely that an increasing 
number of patients requiring treatment will have to receive parenteral therapy instead of an oral 
triazole agent. 
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Infections caused by Candida spp. 
Invasive candidiasis (IC) is the most common invasive fungal infection in the developed world and 
has strong associations with medical intervention, in particular central venous catheters, recent 
(most commonly intra-abdominal) surgery and broad-spectrum antimicrobial use [32]. The incidence 
of IC is increasing, [33, 34] and is particularly common in critical care environments. The 
epidemiology will differ depending on the patient cohort treated, trends of antifungal use, and 
geographically [35]. With the increased use of fluconazole, the incidence of inherently fluconazole 
resistant spp. such as C. glabrata and C. krusei increases [36, 37]. Additionally, echinocandin 
resistance is now recognised to occur, and is as high as 12% of Candida spp. in some series[38]. The 
emergence of multi-drug resistant Candida spp. such as Candida auris will add to the challenge of 
treating IC, and may increase the need to consider OPAT in the treatment of these patients [39].  
 
Obtaining a microbiological diagnosis in invasive candidosis can be difficult, with sensitivity of blood 
cultures being estimated at approximately 50% in patients with invasive candidiasis [40]. While 
antimicrobial resistance in community-acquired Candida spp. infections is uncommon, triazole 
resistance is more commonly found in nosocomial isolates. Triazole resistance has implications for 
the choice of therapy, as invasive infections with resistant strains will require parenteral therapy 
with an echinocandin or liposomal amphotericin B for the duration of treatment required. This could 
be facilitated through an OPAT service once the patient is deemed clinically stable and fit for 
hospital discharge.  
 
Echinocandins have demonstrated superiority in the management of candidaemia, in particular in 
critically ill patients, and as such are recommended as first line therapy [41, 42]. Many patients with 
infections caused by species such as Candida albicans which are generally susceptible to fluconazole 
can be de-escalated to oral fluconazole for ongoing therapy once clinically stable and blood cultures 
on treatment are negative [29, 43]. The current recommendation is 10 days of IV echinocandin prior 
to de-escalation to fluconazole. Echinocandins should generally not be used in infections caused by 
C. parapsilosis due to theoretical concerns of risk of treatment failure based on the increased MICs 
to echinocandins exhibited by this species [29].  
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With the recent identification of Candida auris as a worldwide cause of multi-drug resistant 
outbreaks, increasing use of parenteral antifungal agents in the treatment of Candida spp. infections 
appears likely, and the traditional oral stepdown to fluconazole may not be a therapeutic option 
[39].  
 
Candida spp. infections that would be particularly suited to OPAT would be uncomplicated 
candidaemia and deep-seated infections such as osteoarticular or endovascular infections. Patients 
with candidaemia are at risk of disseminated disease. As a result, all patients with candidaemia 
should be evaluated for endophthalmitis and endocarditis. Dilated retinal examination should be 
undertaken to exclude ocular involvement [29]. Surveillance blood culture monitoring is required to 
ensure candidaemia has been successfully cleared with parenteral antifungal therapy. 
Echocardiography should be undertaken to assess for endocarditis. Following clearance of blood 
cultures, patients with uncomplicated candidaemia require 14 days of therapy [29, 43]. This is likely 
to necessitate inpatient therapy initially but if stable patients could rapidly be transitioned to care on 
OPAT to complete their therapy. 
 
Candida endocarditis and osteoarticular infections require prolonged therapy, usually in 
combination with surgery [29, 43]. Following a period of inpatient therapy, when stable these 
patients could be suitable for treatment via OPAT following surgical intervention. While triazoles 
show poor penetration into biofilms and vegetations, liposomal amphotericin B and echinocandins 
exhibit better activity against biofilms associated with Candida spp.[44]. These infections require 
collaboration with surgical colleagues to ensure adequate source control is undertaken; in patients 
with endocarditis, valve replacement should be pursued, while in septic arthritis surgical drainage 
should be performed [29]. Assuming there is clearance of bloodstream infection and the patient is 
stable, therapy can often be de-escalated to an oral triazole in patients with infections caused 
susceptible Candida isolates, although in non-susceptible isolates parenteral echinocandin or 
liposomal amphotericin B could be delivered via OPAT. 
 
Chronic hepatosplenic candidiasis also requires prolonged antifungal therapy until there is resolution 
on imaging, often for months. Initial therapy for the first few weeks should be with an echinocandin 
or liposomal amphotericin B before stepping down to oral fluconazole if the isolate is fluconazole 
susceptible, or if the risk of fluconazole resistance is deemed to be low [29].  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The spectrum of infections caused by Candida spp. is diverse but many patients could be considered 
for OPAT early in the course of their illness if clinically stable, investigations for metastatic disease 
have been carried out, and are otherwise fit for discharge. Echinocandins remain the initial therapy 
of choice for invasive infections, with current recommendations stating therapy should be continued 
for a minimum of 10 days before switch to oral azole is considered where appropriate [43]. In 
patients with complicated disease or resistant isolates, where oral therapy may not be an option, 
therapy on OPAT should be pursued if stable. 
 
Infections caused by Aspergillus spp. 
Infections caused by Aspergillus spp., including invasive aspergillosis (IA), chronic pulmonary 
aspergillosis (CPA) and osteoarticular infections may be amenable to therapy with OPAT. Due to 
underlying comorbidities, patients with IA are likely to require stabilisation with inpatient therapy 
prior to consideration of discharge, whereas patients with CPA are more likely to be ambulant [45]. 
While triazoles remain as first line therapy for infections due to Aspergillus spp., liposomal 
Amphotericin B and echinocandins may be used for a variety of reasons, including azole intolerance, 
resistance or salvage therapy [18, 46]. Resistant Aspergillus spp. can be acquired from the 
environment, or arise due to previous triazole exposure, and patterns of resistance may differ [47]. 
The risks for the development of resistance while on triazole therapy include; the burden of 
Aspergillus infection, subtherapeutic serum triazole levels, and patient nonadherence [45]. Triazole 
resistance has been increasingly identified in Aspergillus fumigatus, particularly in Europe. The 
prevalence of triazole resistance in A. fumigatus is approx. 3.2% with some European countries 
reporting resistance rates as high as 26%[48]. Mutations in the cyp51A gene which encodes fungal 
lanosterol 14a-demethylase, the target of azoles, has led to the development of pan-azole resistant 
A. fumigatus isolates[47].  
 
It should be noted that while the echinocandins may be used as salvage therapy, they are not 
recommended as monotherapy in the primary treatment of IA [18, 46].   
 
The duration of therapy for Aspergillus infection is dependent on the indication. While patients with 
IA generally receive up to 12 weeks of therapy, patients with CPA often receive prolonged triazole 
therapy lasting 6 months or more [18, 46]. When parenteral therapy is considered in CPA patients, 
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short courses of up to 6 weeks or intermittent therapy may be attempted [46]. In patients with CPA, 
short course (2-4 weeks) micafungin is equivalent to voriconazole, with a favourable side effect 
profile [49]. Caspofungin and micafungin appear equivalent in improving the health status of 
patients with CPA [50]. In a small series of patients with sarcoidosis and progressive CPA, cyclical 
caspofungin resulted in stabilisation of radiological appearance and lung function [51]. A 
retrospective study of intravenous liposomal amphotericin B in CPA demonstrated high response 
rates (76.6% for repeated courses <6 weeks duration), but increased risk of acute kidney injury with 
repeated courses of therapy [52]. In general, the use of parenteral therapy in CPA should be 
reserved for patients with progressive disease, triazole resistance, and/or those who fail or are 
intolerant of triazoles [46].  
 
Infections caused by endemic fungi 
The so-called endemic mycoses are a diverse group of dimorphic fungi, including Histoplasma 
capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides brasiliensis and 
Talaromyces marneffei (formerly known as Penicillium marneffei). Varying in severity from mild and 
self-limiting to severe life-threatening infections, some are more commonly seen in patients with 
severe immunocompromise such as advanced HIV infection, particularly histoplasmosis and 
coccidioidomycosis [53]. The endemic fungi are mainly associated with respiratory infections but can 
also cause disseminated disease and meningitis. In general, patients with mild or moderate disease 
are treated with an azole, most commonly itraconazole, but for patients with severe disease 
amphotericin B is recommended as initial therapy [54]. Duration of therapy is generally a minimum 
of 2 weeks parenteral therapy before consideration of de-escalation to an oral azole. A recent 
randomised controlled trial in patients with HIV-associated talaromycosis suggested that induction 
with amphotericin B for 2 weeks is superior to therapy with itraconazole alone with respect to 6-
month mortality and clinical response [55].  
 
Patients with severe manifestations of these infections, necessitating parenteral therapy, are likely 
to require inpatient initiation of therapy prior to consideration of OPAT. In some patients OPAT may 
be precluded by the severity of illness, need for supplementary oxygen or acute organ support. Once 
clinically stable and ambulant, therapy via OPAT could be considered prior to de-escalation to oral 
therapy. 
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Infections caused by Cryptococcus spp. 
Cryptococcus neoformans is the leading cause of fungal meningitis in severely immunocompromised 
patients, particularly in association with HIV infection, with the largest burden of disease found in 
Subsaharan Africa and South East Asia [56]. Induction therapy with liposomal amphotericin B with 
oral flucytosine recommended for a minimum of 2 weeks before switching to oral fluconazole, if 
flucytosine is not included induction therapy is likely to be longer [54]. Cryptococcus gattii, once 
thought to be a subtype of C. neoformans, has been associated with CNS and pulmonary 
manifestations in both immunocompetent and immunocompromised patients; some strains of C. 
gattii, particularly of the VGII molecular type, are associated with reduced susceptibility to 
fluconazole and may require parenteral therapy [57]. 
 
Treatment for Cryptococcosis on OPAT could be considered when the patient is clinically stable and 
no longer has a requirement for regular lumbar puncture to reduce intracranial pressure. Flucytosine 
requires close monitoring for myelosuppression with full blood count. While maintenance therapy is 
usually in the form of fluconazole, an alternative approach is weekly liposomal amphotericin B, 
particularly in the case of azole intolerance [58].  
 
Mucormycosis 
Mucorales can cause aggressive rhino-orbital, pulmonary, cutaneous or disseminated infections in 
patients with severe immunocompromise, neutropenia or diabetes [59]. The most commonly 
associated organisms include Rhizopus, Mucor, Lichtheimia, Cunninghamella and Rhizomucor.  
Amphotericin B remains the recommended first line therapy, with isavuconazole or posaconazole as 
alternatives [60, 61]. The optimal duration of therapy is not clear. Patients with rhino-orbital and 
cutaneous disease require surgical intervention [60]. Those who require ongoing surgical review and 
debridement should not be considered for OPAT until surgical excision is considered complete. 
When surgical management is no longer needed, following physiological stabilisation, continuation 
of therapy with liposomal amphotericin B on OPAT could be considered, provided close follow up 
with an infection specialist is available.  
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Infections caused by Fusarium spp. 
After Aspergillus spp, Fusarium spp. is the most common pathogenic mould seen in the setting of 
solid organ transplant recipients or patients with haematological malignancy, usually presenting as 
persistent fever with evidence of cutaneous or sinopulmonary disease. Voriconazole or amphotericin 
B should used in conjunction with surgical debridement, where possible [62]. As with IA and 
mucormycosis, where localised disease can be surgically excised, OPAT could be considered when 
surgical debridement is deemed to be complete, immunocompromise has improved and 
physiological stability has been achieved. After a period of parenteral therapy, patients with 
fusariosis may be able to transition to oral triazole to continue prolonged treatment, potentially with 
a period of secondary prophylaxis, such an approach could be successfully managed in the 
controlled environment of an OPAT service.  
 
Conclusions 
With regards to the treatment of fungal infections, OPAT is an underutilised method of delivering 
therapy. There is a paucity of clinical experience and, as a result, little published data to guide 
clinicians in practice. The increase in azole resistance, particularly in Aspergillus spp., makes it likely 
that second line therapy with amphotericin B or an echinocandin will become increasingly common. 
The use of OPAT to deliver parenteral therapy in the treatment of multi-drug resistant Candida auris, 
now identified as an emerging cause of hospital outbreaks, could reduce risk of ongoing 
nosocominal transmission. While many patients with fungal infections have significant 
comorbidities, the ability of OPAT to facilitate delivery of treatment in the community should not be 
overlooked, improving patients’ quality of life and providing them with the opportunity to spend 
more time with family and friends. A carefully selected cohort of patients could benefit from OPAT 
and this should be considered by clinicians responsible for their care. 
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Table 1. Patient selection considerations for OPAT 
 
Patient Selection for OPAT 
 
Issues specific to antifungal therapy administered 
via OPAT 
 The OPAT clinical lead should devise 
specific infection-related inclusion and 
exclusion criteria 
 
 The patient must have the ability to 
understand the concept of OPAT and to 
comply with proposed treatment 
 
 Monitoring whilst on OPAT mandates 
that the patient have access to weekly 
outpatient review 
 
 
 The patient must have the ability to 
self-report an adverse event or a 
clinical deterioration 
 
 Written consent prior to commencing 
OPAT ensures that the patient 
understands the potential adverse drug 
events that may occur on antifungal 
therapy. 
 
 
 Enhanced medications reconciliation; 
focusing particularly on the potential for 
drug-drug interactions e.g. with warfarin.  
 
 Enhanced monitoring; ensuring there is a 
method to monitor for potential 
electrolyte disturbances and 
nephrotoxicity, particularly early in  the 
course of therapy.  
 
 First dose administration; ensuring a 
system is in place to administer first doses 
of intravenous antifungals in a healthcare 
setting due to the potential for infusion 
reactions.  
 
 Outpatient management provided by an 
infection specialist, skilled in the area of 
medical mycology. 
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Table 2. Proposed recommendations for treatment of fungal infections on OPAT 
Antifungal Infection Follow-up Monitoring / 
Considerations 
Echinocandins 
(Caspofungin, 
micafungin, 
anidulafungin) 
Candida spp. 
Bloodstream infection 
(provided blood cultures 
have cleared) 
Endocarditis 
Hepatosplenic candidiasis 
Osteoarticular infection 
Review once / twice 
weekly 
 
Should not be used for 
C. parapsilosis 
 
 
Weekly: 
Full blood count 
Liver function tests 
 Aspergillus spp. 
Invasive aspergillosis 
Chronic pulmonary 
aspergillosis 
Osteoarticular infection 
Review once / twice 
weekly 
 
CPA: 
Repeat CT thorax in 3-
6 months 
 
IA: 
Repeat high-
resolution CT after 
minimum 2 weeks 
therapy 
Weekly: 
Full blood count 
Liver function tests 
 
Liposomal 
Amphotericin B 
Candida spp. 
Bloodstream infection 
(provided blood cultures 
have cleared) 
Endocarditis 
Hepatosplenic candidiasis 
Osteoarticular infection 
Review once / twice 
weekly 
 
Twice weekly 
Renal function 
 
Weekly: 
Full blood count 
Liver function tests 
Magnesium 
 Aspergillus spp. 
Invasive aspergillosis 
Chronic pulmonary 
aspergillosis 
Osteoarticular infection 
Review once / twice 
weekly 
 
CPA: 
Repeat CT thorax in 3-
Twice weekly 
Renal function 
 
Weekly: 
Full blood count 
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6 months 
 
IA: 
Repeat high-
resolution CT after 
minimum 2 weeks 
therapy 
Liver function tests 
Magnesium 
 
Should not be used for 
infections with A. 
terreus or A. nidulans 
 Endemic fungi 
Pneumonia 
Disseminated disease 
Review once / twice 
weekly 
 
 
Consider switch to 
oral azole after 
minimum of 14 days 
therapy 
 
Twice weekly 
Renal function 
 
Weekly: 
Full blood count 
Liver function tests 
Magnesium 
 Cryptococcus spp. 
Meningo-encephalitis 
Disseminated disease 
Review twice weekly 
 
If recurrence of 
symptoms: 
Lumbar puncture / 
CSF drainage (may 
need repeated) 
Consider switch to 
oral fluconazole after 
minimum of 14 days 
therapy 
 
Twice weekly 
Renal function 
 
Weekly: 
Full blood count 
Liver function tests 
Magnesium 
 Mucormycosis 
Rhino-orbital disease 
Pulmonary disease 
Review once / twice 
weekly 
Twice weekly 
Renal function 
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Cutaneous disease 
Disseminated 
Weekly: 
Full blood count 
Liver function tests 
Magnesium 
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